The Market Reports
Call: +1-631-407-1315 / +91-750-729-1479
Email: sales@themarketreports.com
Global Antibody Drug Conjugate CDMO Market Research Report 2025
Synopsis
Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.
The global Antibody Drug Conjugate CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Antibody Drug Conjugate CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Antibody Drug Conjugate CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Antibody Drug Conjugate CDMO in Solid Tumors is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Antibody Drug Conjugate CDMO include Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Curia, Novasep, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate CDMO.
The Antibody Drug Conjugate CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Antibody-Drug Conjugate (ADC) is a type of targeted cancer therapy that utilizes monoclonal antibodies to deliver cytotoxic drugs directly to cancer cells, minimizing damage to healthy cells. ADCs have shown promising results in treating various types of cancers.A Contract Development and Manufacturing Organization (CDMO) specializes in providing services related to the development, manufacturing, and testing of pharmaceuticals, including biologics like ADCs.
The global Antibody Drug Conjugate CDMO market was valued at US$ million in 2023 and is anticipated to reach US$ million by 2030, witnessing a CAGR of %during the forecast period 2024-2030.
North American market for Antibody Drug Conjugate CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
Asia-Pacific market for Antibody Drug Conjugate CDMO is estimated to increase from $ million in 2023 to reach $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The global market for Antibody Drug Conjugate CDMO in Solid Tumors is estimated to increase from $ million in 2023 to $ million by 2030, at a CAGR of % during the forecast period of 2024 through 2030.
The major global companies of Antibody Drug Conjugate CDMO include Lonza Group, Merck KGaA, Recipharm, Thermo Fisher Scientific, Abbvie, Piramal Pharma Solutions, Catalent, Sterling Pharma Solutions, Curia, Novasep, etc. In 2023, the world's top three vendors accounted for approximately % of the revenue.
This report aims to provide a comprehensive presentation of the global market for Antibody Drug Conjugate CDMO, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Antibody Drug Conjugate CDMO.
The Antibody Drug Conjugate CDMO market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2023 as the base year, with history and forecast data for the period from 2019 to 2030. This report segments the global Antibody Drug Conjugate CDMO market comprehensively. Regional market sizes, concerning products by Type, by Application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Antibody Drug Conjugate CDMO companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by Type, by Application, and by regions.
Market Segmentation
By Company
Lonza Group
Merck KGaA
Recipharm
Thermo Fisher Scientific
Abbvie
Piramal Pharma Solutions
Catalent
Sterling Pharma Solutions
Curia
Novasep
Ajinomoto Bio-Pharma Services
BSP Pharmaceuticals
Cerbios-Pharma
Goodwin Biotechnology
Segment by Type
IgG1
IgG4
Segment by Application
Solid Tumors
Hematological Malignancies
By Region
North America
United States
Canada
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Europe
Germany
France
U.K.
Italy
Russia
Nordic Countries
Rest of Europe
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by Type, by Application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Antibody Drug Conjugate CDMO company competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by Type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by Application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.
Index1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type: 2019 VS 2023 VS 2030
1.2.2 IgG1
1.2.3 IgG4
1.3 Market by Application
1.3.1 Global Antibody Drug Conjugate CDMO Market Growth by Application: 2019 VS 2023 VS 2030
1.3.2 Solid Tumors
1.3.3 Hematological Malignancies
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Antibody Drug Conjugate CDMO Market Perspective (2019-2030)
2.2 Global Antibody Drug Conjugate CDMO Growth Trends by Region
2.2.1 Global Antibody Drug Conjugate CDMO Market Size by Region: 2019 VS 2023 VS 2030
2.2.2 Antibody Drug Conjugate CDMO Historic Market Size by Region (2019-2024)
2.2.3 Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2025-2030)
2.3 Antibody Drug Conjugate CDMO Market Dynamics
2.3.1 Antibody Drug Conjugate CDMO Industry Trends
2.3.2 Antibody Drug Conjugate CDMO Market Drivers
2.3.3 Antibody Drug Conjugate CDMO Market Challenges
2.3.4 Antibody Drug Conjugate CDMO Market Restraints
3 Competition Landscape by Key Players
3.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue
3.1.1 Global Top Antibody Drug Conjugate CDMO Players by Revenue (2019-2024)
3.1.2 Global Antibody Drug Conjugate CDMO Revenue Market Share by Players (2019-2024)
3.2 Global Antibody Drug Conjugate CDMO Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players Ranking by Antibody Drug Conjugate CDMO Revenue
3.4 Global Antibody Drug Conjugate CDMO Market Concentration Ratio
3.4.1 Global Antibody Drug Conjugate CDMO Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Antibody Drug Conjugate CDMO Revenue in 2023
3.5 Global Key Players of Antibody Drug Conjugate CDMO Head office and Area Served
3.6 Global Key Players of Antibody Drug Conjugate CDMO, Product and Application
3.7 Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Antibody Drug Conjugate CDMO Breakdown Data by Type
4.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Type (2019-2024)
4.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2025-2030)
5 Antibody Drug Conjugate CDMO Breakdown Data by Application
5.1 Global Antibody Drug Conjugate CDMO Historic Market Size by Application (2019-2024)
5.2 Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2025-2030)
6 North America
6.1 North America Antibody Drug Conjugate CDMO Market Size (2019-2030)
6.2 North America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
6.3 North America Antibody Drug Conjugate CDMO Market Size by Country (2019-2024)
6.4 North America Antibody Drug Conjugate CDMO Market Size by Country (2025-2030)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Antibody Drug Conjugate CDMO Market Size (2019-2030)
7.2 Europe Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
7.3 Europe Antibody Drug Conjugate CDMO Market Size by Country (2019-2024)
7.4 Europe Antibody Drug Conjugate CDMO Market Size by Country (2025-2030)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Antibody Drug Conjugate CDMO Market Size (2019-2030)
8.2 Asia-Pacific Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
8.3 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2019-2024)
8.4 Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2025-2030)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Antibody Drug Conjugate CDMO Market Size (2019-2030)
9.2 Latin America Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
9.3 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2019-2024)
9.4 Latin America Antibody Drug Conjugate CDMO Market Size by Country (2025-2030)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Antibody Drug Conjugate CDMO Market Size (2019-2030)
10.2 Middle East & Africa Antibody Drug Conjugate CDMO Market Growth Rate by Country: 2019 VS 2023 VS 2030
10.3 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2019-2024)
10.4 Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2025-2030)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Lonza Group
11.1.1 Lonza Group Company Details
11.1.2 Lonza Group Business Overview
11.1.3 Lonza Group Antibody Drug Conjugate CDMO Introduction
11.1.4 Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.1.5 Lonza Group Recent Development
11.2 Merck KGaA
11.2.1 Merck KGaA Company Details
11.2.2 Merck KGaA Business Overview
11.2.3 Merck KGaA Antibody Drug Conjugate CDMO Introduction
11.2.4 Merck KGaA Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.2.5 Merck KGaA Recent Development
11.3 Recipharm
11.3.1 Recipharm Company Details
11.3.2 Recipharm Business Overview
11.3.3 Recipharm Antibody Drug Conjugate CDMO Introduction
11.3.4 Recipharm Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.3.5 Recipharm Recent Development
11.4 Thermo Fisher Scientific
11.4.1 Thermo Fisher Scientific Company Details
11.4.2 Thermo Fisher Scientific Business Overview
11.4.3 Thermo Fisher Scientific Antibody Drug Conjugate CDMO Introduction
11.4.4 Thermo Fisher Scientific Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.4.5 Thermo Fisher Scientific Recent Development
11.5 Abbvie
11.5.1 Abbvie Company Details
11.5.2 Abbvie Business Overview
11.5.3 Abbvie Antibody Drug Conjugate CDMO Introduction
11.5.4 Abbvie Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.5.5 Abbvie Recent Development
11.6 Piramal Pharma Solutions
11.6.1 Piramal Pharma Solutions Company Details
11.6.2 Piramal Pharma Solutions Business Overview
11.6.3 Piramal Pharma Solutions Antibody Drug Conjugate CDMO Introduction
11.6.4 Piramal Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.6.5 Piramal Pharma Solutions Recent Development
11.7 Catalent
11.7.1 Catalent Company Details
11.7.2 Catalent Business Overview
11.7.3 Catalent Antibody Drug Conjugate CDMO Introduction
11.7.4 Catalent Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.7.5 Catalent Recent Development
11.8 Sterling Pharma Solutions
11.8.1 Sterling Pharma Solutions Company Details
11.8.2 Sterling Pharma Solutions Business Overview
11.8.3 Sterling Pharma Solutions Antibody Drug Conjugate CDMO Introduction
11.8.4 Sterling Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.8.5 Sterling Pharma Solutions Recent Development
11.9 Curia
11.9.1 Curia Company Details
11.9.2 Curia Business Overview
11.9.3 Curia Antibody Drug Conjugate CDMO Introduction
11.9.4 Curia Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.9.5 Curia Recent Development
11.10 Novasep
11.10.1 Novasep Company Details
11.10.2 Novasep Business Overview
11.10.3 Novasep Antibody Drug Conjugate CDMO Introduction
11.10.4 Novasep Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.10.5 Novasep Recent Development
11.11 Ajinomoto Bio-Pharma Services
11.11.1 Ajinomoto Bio-Pharma Services Company Details
11.11.2 Ajinomoto Bio-Pharma Services Business Overview
11.11.3 Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Introduction
11.11.4 Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.11.5 Ajinomoto Bio-Pharma Services Recent Development
11.12 BSP Pharmaceuticals
11.12.1 BSP Pharmaceuticals Company Details
11.12.2 BSP Pharmaceuticals Business Overview
11.12.3 BSP Pharmaceuticals Antibody Drug Conjugate CDMO Introduction
11.12.4 BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.12.5 BSP Pharmaceuticals Recent Development
11.13 Cerbios-Pharma
11.13.1 Cerbios-Pharma Company Details
11.13.2 Cerbios-Pharma Business Overview
11.13.3 Cerbios-Pharma Antibody Drug Conjugate CDMO Introduction
11.13.4 Cerbios-Pharma Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.13.5 Cerbios-Pharma Recent Development
11.14 Goodwin Biotechnology
11.14.1 Goodwin Biotechnology Company Details
11.14.2 Goodwin Biotechnology Business Overview
11.14.3 Goodwin Biotechnology Antibody Drug Conjugate CDMO Introduction
11.14.4 Goodwin Biotechnology Revenue in Antibody Drug Conjugate CDMO Business (2019-2024)
11.14.5 Goodwin Biotechnology Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.1.1 Research Programs/Design
13.1.1.2 Market Size Estimation
13.1.1.3 Market Breakdown and Data Triangulation
13.1.2 Data Source
13.1.2.1 Secondary Sources
13.1.2.2 Primary Sources
13.2 Author Details
13.3 Disclaimer
List of TablesList of Tables
Table 1. Global Antibody Drug Conjugate CDMO Market Size Growth Rate by Type (US$ Million): 2019 VS 2023 VS 2030
Table 2. Key Players of IgG1
Table 3. Key Players of IgG4
Table 4. Global Antibody Drug Conjugate CDMO Market Size Growth by Application (US$ Million): 2019 VS 2023 VS 2030
Table 5. Global Antibody Drug Conjugate CDMO Market Size by Region (US$ Million): 2019 VS 2023 VS 2030
Table 6. Global Antibody Drug Conjugate CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 7. Global Antibody Drug Conjugate CDMO Market Share by Region (2019-2024)
Table 8. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Region (2025-2030) & (US$ Million)
Table 9. Global Antibody Drug Conjugate CDMO Market Share by Region (2025-2030)
Table 10. Antibody Drug Conjugate CDMO Market Trends
Table 11. Antibody Drug Conjugate CDMO Market Drivers
Table 12. Antibody Drug Conjugate CDMO Market Challenges
Table 13. Antibody Drug Conjugate CDMO Market Restraints
Table 14. Global Antibody Drug Conjugate CDMO Revenue by Players (2019-2024) & (US$ Million)
Table 15. Global Antibody Drug Conjugate CDMO Market Share by Players (2019-2024)
Table 16. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2023)
Table 17. Ranking of Global Top Antibody Drug Conjugate CDMO Companies by Revenue (US$ Million) in 2023
Table 18. Global 5 Largest Players Market Share by Antibody Drug Conjugate CDMO Revenue (CR5 and HHI) & (2019-2024)
Table 19. Global Key Players of Antibody Drug Conjugate CDMO, Headquarters and Area Served
Table 20. Global Key Players of Antibody Drug Conjugate CDMO, Product and Application
Table 21. Global Key Players of Antibody Drug Conjugate CDMO, Date of Enter into This Industry
Table 22. Mergers & Acquisitions, Expansion Plans
Table 23. Global Antibody Drug Conjugate CDMO Market Size by Type (2019-2024) & (US$ Million)
Table 24. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2019-2024)
Table 25. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Type (2025-2030) & (US$ Million)
Table 26. Global Antibody Drug Conjugate CDMO Revenue Market Share by Type (2025-2030)
Table 27. Global Antibody Drug Conjugate CDMO Market Size by Application (2019-2024) & (US$ Million)
Table 28. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2019-2024)
Table 29. Global Antibody Drug Conjugate CDMO Forecasted Market Size by Application (2025-2030) & (US$ Million)
Table 30. Global Antibody Drug Conjugate CDMO Revenue Market Share by Application (2025-2030)
Table 31. North America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 32. North America Antibody Drug Conjugate CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 33. North America Antibody Drug Conjugate CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 34. Europe Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 35. Europe Antibody Drug Conjugate CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 36. Europe Antibody Drug Conjugate CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 37. Asia-Pacific Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 38. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2019-2024) & (US$ Million)
Table 39. Asia-Pacific Antibody Drug Conjugate CDMO Market Size by Region (2025-2030) & (US$ Million)
Table 40. Latin America Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 41. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 42. Latin America Antibody Drug Conjugate CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 43. Middle East & Africa Antibody Drug Conjugate CDMO Market Size Growth Rate by Country (US$ Million): 2019 VS 2023 VS 2030
Table 44. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2019-2024) & (US$ Million)
Table 45. Middle East & Africa Antibody Drug Conjugate CDMO Market Size by Country (2025-2030) & (US$ Million)
Table 46. Lonza Group Company Details
Table 47. Lonza Group Business Overview
Table 48. Lonza Group Antibody Drug Conjugate CDMO Product
Table 49. Lonza Group Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 50. Lonza Group Recent Development
Table 51. Merck KGaA Company Details
Table 52. Merck KGaA Business Overview
Table 53. Merck KGaA Antibody Drug Conjugate CDMO Product
Table 54. Merck KGaA Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 55. Merck KGaA Recent Development
Table 56. Recipharm Company Details
Table 57. Recipharm Business Overview
Table 58. Recipharm Antibody Drug Conjugate CDMO Product
Table 59. Recipharm Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 60. Recipharm Recent Development
Table 61. Thermo Fisher Scientific Company Details
Table 62. Thermo Fisher Scientific Business Overview
Table 63. Thermo Fisher Scientific Antibody Drug Conjugate CDMO Product
Table 64. Thermo Fisher Scientific Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 65. Thermo Fisher Scientific Recent Development
Table 66. Abbvie Company Details
Table 67. Abbvie Business Overview
Table 68. Abbvie Antibody Drug Conjugate CDMO Product
Table 69. Abbvie Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 70. Abbvie Recent Development
Table 71. Piramal Pharma Solutions Company Details
Table 72. Piramal Pharma Solutions Business Overview
Table 73. Piramal Pharma Solutions Antibody Drug Conjugate CDMO Product
Table 74. Piramal Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 75. Piramal Pharma Solutions Recent Development
Table 76. Catalent Company Details
Table 77. Catalent Business Overview
Table 78. Catalent Antibody Drug Conjugate CDMO Product
Table 79. Catalent Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 80. Catalent Recent Development
Table 81. Sterling Pharma Solutions Company Details
Table 82. Sterling Pharma Solutions Business Overview
Table 83. Sterling Pharma Solutions Antibody Drug Conjugate CDMO Product
Table 84. Sterling Pharma Solutions Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 85. Sterling Pharma Solutions Recent Development
Table 86. Curia Company Details
Table 87. Curia Business Overview
Table 88. Curia Antibody Drug Conjugate CDMO Product
Table 89. Curia Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 90. Curia Recent Development
Table 91. Novasep Company Details
Table 92. Novasep Business Overview
Table 93. Novasep Antibody Drug Conjugate CDMO Product
Table 94. Novasep Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 95. Novasep Recent Development
Table 96. Ajinomoto Bio-Pharma Services Company Details
Table 97. Ajinomoto Bio-Pharma Services Business Overview
Table 98. Ajinomoto Bio-Pharma Services Antibody Drug Conjugate CDMO Product
Table 99. Ajinomoto Bio-Pharma Services Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 100. Ajinomoto Bio-Pharma Services Recent Development
Table 101. BSP Pharmaceuticals Company Details
Table 102. BSP Pharmaceuticals Business Overview
Table 103. BSP Pharmaceuticals Antibody Drug Conjugate CDMO Product
Table 104. BSP Pharmaceuticals Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 105. BSP Pharmaceuticals Recent Development
Table 106. Cerbios-Pharma Company Details
Table 107. Cerbios-Pharma Business Overview
Table 108. Cerbios-Pharma Antibody Drug Conjugate CDMO Product
Table 109. Cerbios-Pharma Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 110. Cerbios-Pharma Recent Development
Table 111. Goodwin Biotechnology Company Details
Table 112. Goodwin Biotechnology Business Overview
Table 113. Goodwin Biotechnology Antibody Drug Conjugate CDMO Product
Table 114. Goodwin Biotechnology Revenue in Antibody Drug Conjugate CDMO Business (2019-2024) & (US$ Million)
Table 115. Goodwin Biotechnology Recent Development
Table 116. Research Programs/Design for This Report
Table 117. Key Data Information from Secondary Sources
Table 118. Key Data Information from Primary Sources
Table 119. Authors List of This Report
List of Figures
Figure 1. Antibody Drug Conjugate CDMO Picture
Figure 2. Global Antibody Drug Conjugate CDMO Market Size Comparison by Type (2024-2030) & (US$ Million)
Figure 3. Global Antibody Drug Conjugate CDMO Market Share by Type: 2023 VS 2030
Figure 4. IgG1 Features
Figure 5. IgG4 Features
Figure 6. Global Antibody Drug Conjugate CDMO Market Size by Application (2024-2030) & (US$ Million)
Figure 7. Global Antibody Drug Conjugate CDMO Market Share by Application: 2023 VS 2030
Figure 8. Solid Tumors Case Studies
Figure 9. Hematological Malignancies Case Studies
Figure 10. Antibody Drug Conjugate CDMO Report Years Considered
Figure 11. Global Antibody Drug Conjugate CDMO Market Size (US$ Million), Year-over-Year: 2019-2030
Figure 12. Global Antibody Drug Conjugate CDMO Market Size, (US$ Million), 2019 VS 2023 VS 2030
Figure 13. Global Antibody Drug Conjugate CDMO Market Share by Region: 2023 VS 2030
Figure 14. Global Antibody Drug Conjugate CDMO Market Share by Players in 2023
Figure 15. Global Top Antibody Drug Conjugate CDMO Players by Company Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue in Antibody Drug Conjugate CDMO as of 2023)
Figure 16. The Top 10 and 5 Players Market Share by Antibody Drug Conjugate CDMO Revenue in 2023
Figure 17. North America Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 18. North America Antibody Drug Conjugate CDMO Market Share by Country (2019-2030)
Figure 19. United States Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 20. Canada Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 21. Europe Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 22. Europe Antibody Drug Conjugate CDMO Market Share by Country (2019-2030)
Figure 23. Germany Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 24. France Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 25. U.K. Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 26. Italy Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 27. Russia Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 28. Nordic Countries Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 29. Asia-Pacific Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 30. Asia-Pacific Antibody Drug Conjugate CDMO Market Share by Region (2019-2030)
Figure 31. China Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 32. Japan Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 33. South Korea Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 34. Southeast Asia Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 35. India Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 36. Australia Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 37. Latin America Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 38. Latin America Antibody Drug Conjugate CDMO Market Share by Country (2019-2030)
Figure 39. Mexico Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 40. Brazil Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 41. Middle East & Africa Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 42. Middle East & Africa Antibody Drug Conjugate CDMO Market Share by Country (2019-2030)
Figure 43. Turkey Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 44. Saudi Arabia Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 45. UAE Antibody Drug Conjugate CDMO Market Size YoY Growth (2019-2030) & (US$ Million)
Figure 46. Lonza Group Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 47. Merck KGaA Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 48. Recipharm Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 49. Thermo Fisher Scientific Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 50. Abbvie Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 51. Piramal Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 52. Catalent Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 53. Sterling Pharma Solutions Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 54. Curia Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 55. Novasep Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 56. Ajinomoto Bio-Pharma Services Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 57. BSP Pharmaceuticals Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 58. Cerbios-Pharma Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 59. Goodwin Biotechnology Revenue Growth Rate in Antibody Drug Conjugate CDMO Business (2019-2024)
Figure 60. Bottom-up and Top-down Approaches for This Report
Figure 61. Data Triangulation
Figure 62. Key Executives Interviewed
Published By : QY Research
Why ‘The Market Reports’
In Business:
Pre Sales Support:
Post Sales Support:
Turn Around Time:
Clients Served:
Clients Assisted:
Client Types:
Payment:
- Accept global payments [Credit Card / PayPal / Wire Transfer]
- Accept local payments in South Korea, Germany, China and India [Can pay in local currency]
Latest Life Science Market Reports
Payments Accepted From
Connect with us at
Complete Secure Website
